BioNotebook: Forest, Epizyme raise cash; Geron falls on imetelstat update; Revance sets IPO terms
This article was originally published in Scrip
Executive Summary
Forest Laboratories is taking on $1.8bn in debt through the sale of senior unsecured fixed-rate notes to finance its $2.9bn acquisition of Aptalis, but on a down day for biotechnology and specialty pharmaceutical stocks in general the New York-based company closed slightly higher with a 0.3% boost to $65.14 per share on 27 January.